^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    milciclib (TZLS-201)

    i
    Other names: TZLS-201, PHA-848125, PHA 848125C, PHA-125, PHA-848125AC, PHA848125C, PHA848125, PHA 848125, PHA125, PHA 125, TZLS201, TZLS 201, PHA848125AC, PHA 848125AC, PHA-848125C
    Associations

    News

    Trials
    Company:
    Nerviano Medical Sciences, Tiziana Life Sci
    Drug class:
    TrkA receptor antagonist, pan-CDK inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. (PubMed, Cancer Cell)
    We functionally validated 16 drug targets identified through integrated spatial transcriptomics and proteomics. Combined treatment targeting CDK4/6 (milciclib) and FOLR1 (mirvetuximab) achieved significant tumor reduction in vivo, representing a promising therapeutic strategy for LGSC.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • FOLR1 ( Folate receptor alpha ) • CDK4 (Cyclin-dependent kinase 4)
    |
    MET overexpression
    |
    milciclib (TZLS-201)
    8ms
    Milciclib-mediated CDK2 inhibition to boost radiotherapy sensitivity in colorectal cancer. (PubMed, Front Pharmacol)
    It disrupts the G2/M checkpoint and impairs DNA repair mechanisms. These findings suggest that Milciclib has the potential to be an effective therapeutic agent for CRC.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    milciclib (TZLS-201)
    over1year
    IFIH1-mediated post-transcriptional regulation of PTTG1 promotes proliferation and affects PHA-848125 sensitivity and prognosis in oropharyngeal carcinoma. (PubMed, Am J Cancer Res)
    We found that the IFIH1-PTTG1 axis could regulate the PHA-848125 response and functionally mediate inter-individual oropharyngeal cancer susceptibility and prognosis. This study aimed to confirm the upstream regulatory genes of PTTG1 and further investigate the specific interactions in this signaling pathway, which will provide a new approach for the treatment of oropharyngeal carcinoma.
    Journal
    |
    PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    milciclib (TZLS-201)
    2years
    Comprehensive analysis of cuproptosis genes and cuproptosis-related genes as prognosis factors in esophageal squamous cell carcinoma. (PubMed, Genomics)
    The results also showed that milciclib might inhibit the proliferation and migration of KYSE150 and KYSE510 cells by targeting CDKN2A. In conclusion, the abovementioned CUGs and CRGs play a crucial role in tumorigenesis and cancer progression in ESCC, indicating their potential as therapeutic targets.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BTLA (B And T Lymphocyte Associated) • DLAT (Dihydrolipoamide S-Acetyltransferase) • MELTF (Melanotransferrin) • PRRX1 (Paired Related Homeobox 1) • FDX1 (Ferredoxin 1) • LIAS (Lipoic Acid Synthetase) • LIPT1 (Lipoyltransferase 1) • PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1)
    |
    milciclib (TZLS-201)
    almost3years
    Milciclib in Combination With Gemcitabine in Advanced NSCLC (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Tiziana Life Sciences LTD
    New P2 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13
    |
    gemcitabine • milciclib (TZLS-201)